Loading
Latest filing published 24 Jul 2025 for Hansa Biopharma AB. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Anne Säfström Lanner (board member) discloses dealings in Hansa Biopharma AB to Finansinspektionen. In total, 2 filings cover trades dated 22 July 2025.
Market trades split into 1 purchase and 1 sale (€19k). The totals do not cover 1 filing with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
The record was last updated on 24 July 2025 with an open-market purchase in Hansa Biopharma AB. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations